In the first clinical trial [NCT03432364; ST-400-01] by Sangamo Therapeutics and Sanofi, rapid hematologic reconstitution, HbF elevation and a persistence of editing rate was observed six months after transplantation in thalassemic patients, while SCD patients remained symptom-free for up to 52 weeks post CD34+-edited cell transplantation [12]. This evidence concerns the gene CD34 and Schnyder corneal dystrophy.